Form 4 for JAZZ Jazz Pharmaceuticals plc
Accepted 2025-12-01 00:00:00 ET · period of report 2025-11-26 · accession 0001193210-25-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-01 | 2025-11-26 | JAZZ | COZADD BRUCE C | Dir | S - Sale+OE | $177.81 | -77.5K | 432.0K | -15% | -$13.78M |
| DM | 2025-12-01 | 2025-11-26 | JAZZ | COZADD BRUCE C | Dir | M - OptEx | $123.36 | +77.5K | 470.8K | +20% | +$9.56M |
| DM | 2025-12-01 | 2025-11-26 | JAZZ | COZADD BRUCE C | Dir | M - OptEx | $0.00 | -77.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-11-26 | S | D | 507 | $179.79 | 431,458 | D | — | — | (F3) Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $179.73 to $179.96. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |
| 2 | Common | Ordinary Shares | 2025-11-26 | S | D | 38,126 | $177.27 | 393,332 | D | — | — | (F4) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.70 to $177.69. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |
| 3 | Common | Ordinary Shares | 2025-11-26 | M | A | 76,689 | $123.36 | 470,021 | D | — | — | |
| 4 | Common | Ordinary Shares | 2025-11-26 | M | A | 811 | $123.36 | 470,832 | D | — | — | |
| 5 | Common | Ordinary Shares | 2025-11-26 | S | D | 30,487 | $178.06 | 440,345 | D | — | — | (F1) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $177.70 to $178.685. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |
| 6 | Common | Ordinary Shares | 2025-11-26 | S | D | 8,380 | $179.23 | 431,965 | D | — | — | (F2) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $178.72 to $179.705. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |
| 7 | Derivative | Incentive Stock Option (right to buy) | 2025-11-26 | M | D | 811 | $0.00 | 0 | D | $123.36 · — to 2026-02-24 | 811 Ordinary Shares | (F5) These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. |
| 8 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-11-26 | M | D | 76,689 | $0.00 | 0 | D | $123.36 · — to 2026-02-24 | 76,689 Ordinary Shares | (F5) These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. |